Cargando…
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
Autores principales: | Suarez-Kelly, Lorena P., Levine, Kala M., Olencki, Thomas E., del Campo, Sara E. Martin, Streacker, Elizabeth A., Brooks, Taylor R., Karpa, Volodymyr I., Markowitz, Joseph, Bingman, Anissa K., Geyer, Susan M., Kendra, Kari L., Carson, William E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447692/ https://www.ncbi.nlm.nih.gov/pubmed/30725205 http://dx.doi.org/10.1007/s00262-019-02308-w |
Ejemplares similares
-
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma
por: Suarez, Lorena P., et al.
Publicado: (2016) -
MiR-21 Enhances Melanoma Invasiveness via Inhibition of Tissue Inhibitor of Metalloproteinases 3 Expression: In Vivo Effects of MiR-21 Inhibitor
por: Martin del Campo, Sara E., et al.
Publicado: (2015) -
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
por: Markowitz, Joseph, et al.
Publicado: (2016) -
Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study
por: Campiglio, M., et al.
Publicado: (2013) -
A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)